Conversely, administration of NOS/NMDA-R activators (L-arg and NMDA) worsened the negative effects of MS on behavior and increased nitrite levels and the expression of iNOS, nNOS, NR2A, and NR2B genes in the hippocampus. This evidence concerns the gene NOS1 and myeloid sarcoma.